Trilobine and its natural analogs for use as a drug
AssigneesPierre Fabre Medicament, Centre National de la Recherche Scientifique (CNRS)
InventorsYoann Menon, Christophe Long, François Sautel, Paola B. Arimondo
Life of this patent
Estimating the term…
Abstract
Trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues as DNMT inhibitors for use as a drug for the treatment of cancer and neurological diseases and for cell reprogramming, in particular to prime for chemotherapy or immunotherapy.
Claims15
A method for the treatment of a cancer comprising the administration to a person in need thereof of an effective dose of a compound selected from trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues,
- wherein trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues correspond to the following formula (I):
- wherein:
- represents a double or single bond, and
- when represents a single bond R1, R2 and R3 represent, independently of each other, a hydrogen atom or a methyl group, at least one of said radicals R1, R2 and R3 being a methyl group,
- when represents a double bond R1 and R3 are, independently of each other, a hydrogen atom or a methyl group and R2 is absent,
- or a pharmaceutically acceptable salt or solvate thereof, and
- wherein the cancer is a cancer over-expressing DNA methyl transferase (DNMT).
A method for inhibiting DNA methyl transferase (DNMT) comprising the administration to a person in need thereof of an effective dose of a compound selected from trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues,
- wherein trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues correspond to the following formula (I):
- wherein:
- represents a double or single bond, and
- when represents a single bond R1, R2 and R3 represent, independently of each other, a hydrogen atom or a methyl group, at least one of said radicals R1, R2 and R3 being a methyl group,
- when represents a double bond R1 and R3 are, independently of each other, a hydrogen atom or a methyl group and R2 is absent,
- or a pharmaceutically acceptable salt or solvate thereof.
A method for the treatment of cancer comprising the simultaneous, separate or sequential administration to a person in need thereof of an effective dose of a pharmaceutical product comprising:
- at least one compound selected from trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues, and
- at least another active ingredient,
- wherein trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues correspond to the following formula (I):
- wherein:
- represents a double or single bond, and
- when represents a single bond R1, R2 and R3 represent, independently of each other, a hydrogen atom or a methyl group, at least one of said radicals R1, R2 and R3 being a methyl group,
- when represents a double bond R1 and R3 are, independently of each other, a hydrogen atom or a methyl group and R2 is absent,
- or a pharmaceutically acceptable salt or solvate thereof, and
- wherein the cancer is a cancer over-expressing DNA methyl transferase (DNMT).
A method for the treatment of a cancer comprising the administration to a person in need thereof of an effective dose of a pharmaceutical composition comprising at least one compound selected from trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues, and at least pharmaceutically acceptable excipient,
- wherein trilobine and its natural triple-bridged bisbenzylisoquinoline alkaloidal analogues correspond to the following formula (I):
- wherein:
- represents a double or single bond, and
- when represents a single bond R1, R2 and R3 represent, independently of each other, a hydrogen atom or a methyl group, at least one of said radicals R1, R2 and R3 being a methyl group,
- when represents a double bond R1 and R3 are, independently of each other, a hydrogen atom or a methyl group and R2 is absent,
- or a pharmaceutically acceptable salt or solvate thereof, and
- wherein the cancer is a cancer over-expressing DNA methyl transferase (DNMT).
Dependencies are inferred from the claim text.